Merck & Company (MRK) 57.60 $MRK
If You Live in This State, You May Lose the Choice Whether to Vaccinate Your Kids
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 26, 8:11AM CDT
Source: California State Legislature. California could make it a whole heck of a lot tougher for parents and guardians to choose whether to have their children vaccinated. The Golden State is considering legislation barring the use of the "personal...
MRK: 57.60 (+0.09), GSK: 46.59 (+0.28)
I Called It: What's The Take Home Message?
Pharma Doc - at Seeking Alpha - Sun Apr 26, 12:52AM CDT
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
Merck presents data on two HCV Phase 2s at Liver Meeting
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 6:05PM CDT
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09)
Preliminary data show 100% SVR4 for Viekirax + Exviera
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 4:48PM CDT
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), ENTA: 37.14 (+0.56)
Are Biosimilars the Next Big Thing in Biotech?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 25, 6:06AM CDT
Biologics, or drugs developed from biological sources, have taken the pharma world by storm over the past decade or so. Five of the top 10 best-selling drugs in 2014, for example, were biologics indicated for either autoimmune disorders or cancer. ...
PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 5:28PM CDT
Merck reported encouraging data from an ongoing pivotal phase III program evaluating its grazoprevir/elbasvir.
BIIB: 401.71 (-28.57), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:36PM CDT
AbbVie's (ABBV) experimental HCV treatment is under priority review in the U.S. for the treatment of adults suffering from chronic genotype 4 HCV infection.
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AVEO: 1.92 (-0.08), ABBV: 66.07 (+1.82)
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), PRGO: 192.89 (-8.74), PFE: 35.27 (-0.09), CLDN: 13.68 (-0.26), MYL: 76.06 (+2.37), OREX: 7.36 (-0.08), JNJ: 101.08 (+0.62), NVO: 56.65 (+0.44), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), GILD: 103.69 (-1.52), SGEN: 37.14 (-0.36), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), SNY: 51.75 (-0.01), NBY: 0.63 (unch), XLRN: 33.29 (-0.95)
The Parade of Weak Earnings Reports Continues - Earnings Preview
Sheraz Mian - ZACKS - Fri Apr 24, 2:39PM CDT
The Parade of Weak Earnings Reports Continues - Earnings Preview
ACT: 295.41 (-2.95), F: 15.77 (+0.01), ETN: 68.58 (-0.52), PFE: 35.27 (-0.09), IP: 53.67 (+0.79), COP: 67.51 (-0.75), XOM: 86.97 (-0.57), BAC: 15.64 (-0.05), UPS: 98.10 (-0.12), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), CVS: 101.58 (+0.70), CVX: 109.87 (-0.10), AAPL: 130.28 (+0.61), VIAB: 70.74 (+0.04), MA: 90.72 (-0.16)
'Non-Cyclical Consumer Healthcare': How This Sector Will Create Long-Term Wealth
Peter Mantas - Seeking Alpha - Fri Apr 24, 1:39PM CDT
Allow me to provide you with a hypothetical portfolio containing only 5 stocks. This portfolio is somewhat diversified in that each company operates in different markets with different threats, competitors and opportunities, but all 5 companies have...
MCK: 229.20 (+0.09), AKRX: 55.24 (-0.68), PFE: 35.27 (-0.09), EW: 138.33 (-3.59), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), MOH: 63.85 (-0.13), ORCL: 43.08 (-0.31), CNC: 73.67 (+1.13), JNJ: 101.08 (+0.62), ANTM: 154.28 (+0.08), VRSK: 72.68 (+0.20), GILD: 103.69 (-1.52), RMD: 65.70 (-7.68), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), FICO: 93.85 (+0.55), WCN: 46.52 (+0.32), SRCL: 136.94 (-3.56), SNY: 51.75 (-0.01), ACN: 93.40 (-0.44), NVS: 104.28 (-1.22)
Business events scheduled for the coming week
By The Associated Press - AP - Fri Apr 24, 12:28PM CDT
All times are Eastern.
GT: 27.74 (unch), F: 15.77 (+0.01), V: 67.48 (-0.24), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), CVS: 101.58 (+0.70), XOM: 86.97 (-0.57), BRK.B: 142.09 (-0.34), TWTR: 50.82 (-0.59), BRK.A: 214,490.00 (-250.00), AET: 108.82 (-0.08), AAPL: 130.28 (+0.61)
Merck (MRK) Approaches New Upside Target of $58.28
Comtex SmarTrend(R) - Fri Apr 24, 9:36AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $57.46 today and have reached the first resistance level of $57.89. Should the shares continue to rise, the resistance pivots of $58.28 and $59.09 will be of interest.
MRK: 57.60 (+0.09)
Illumina's Earnings Set Positive Tone for Biotech
Cheryl Swanson, The Motley Fool - Motley Fool - Fri Apr 24, 9:02AM CDT
Illumina just lit up a lot of biotech portfolios. Thanks to record-breaking shipments of gene-sequencing instruments, total quarterly revenue surged 28% to $539 million.. Despite facing currency headwinds, the company handily beat the $524.45...
JNJ: 101.08 (+0.62), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), AMGN: 167.91 (-1.26), ILMN: 189.59 (-3.01), SNY: 51.75 (-0.01)
"Merck More Than A Mother " a new initiative in partnership with Nairobi university and university of Indonesia to address the social suffering of infertile women in Indonesia , Kenya and rest of Africa as part of Merck Capacity Advancement Pro
M2 - Fri Apr 24, 8:14AM CDT
Merck in collaboration with University of Indonesia kicked off two important initiatives "More than A Mother" and "Fertility is a Shared Responsibility" to address the social suffering and stigmatization of infertile women as part of Merck Capacity Advancement program (CAP) in fertility management in Indonesia. Same program will be launched in Kenya in partnership with University of Nairobi.
MRK: 57.60 (+0.09)
Merck's HCV combo shows cure rates of 60 - 100% in three genotypes
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 8:05AM CDT
JNJ: 101.08 (+0.62), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)
Merck Announces Results from C-SURFER Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease
CNW Group - Fri Apr 24, 6:00AM CDT
As well as results from its Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Showing High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
MRK: 57.60 (+0.09)
Global Prepacked Column (1-100 mL, 100-1000 mL, -1L) Market 2015-2019 - Forecasts and Analysis of the $700+ Million Market
M2 - Fri Apr 24, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nvfdmm/prepacked_column) has announced the addition of the "Prepacked Column Market by Type (1-100 mL, 100-1000 mL, -1L) - Global Forecast to 2019" report to their offering. The market for pre-packed disposable columns (typically -1 liter size), was valued at $717.1 million in 2014, and is expected to increase at the highest CAGR from 2014 to 2019 The global prepacked chromatography columns market is estimated to grow at a CAGR of 8.2% from 2014 to 2019. Rising demand of purification of antibodies, recombinant proteins, vaccines; and virus titer reduction are some of the factors driving the growth of pre-packed columns market. The cost-effective purification of biological drugs, specifically monoclonal antibodies (mAbs) has been increasing the market potential of pre-packed columns. However, there is a paradigm shift towards disposable pre-packed columns. In this report, the Global Prepacked Chromatography Columns market is broadly classified on the basis of product types and it includes 1-100 ml, 100-1000 ml, and -1L. The market segmented on the basis of regions covers North America, Europe, Asia-Pacific and Rest of the World (RoW). The market in North America accounted the largest share for 33.6% in 2014, followed by the Asia-Pacific market. Currently, in the U.S., mAbs constitute the single largest biologics product category in the clinical development pipeline including the number of monoclonal antibodies (mAbs) in development and clinical trials, biosimilar developments, and facility expansions using single-use strategies. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Global Prepacked Chromatography Columns Market,By Type 6 Prepacked Chromatography Columns Market,By Geography 7 Global Prepacked Chromatography Columns Market: Competitive Landscape 8 Prepacked Chromatography Columns Market, By Company - Agilent Technologies - Atoll Gmbh - Bio-Rad Laboratories, Inc. - Emd Millipore/ Merck Millipore (A Division Of Merck Kgaa) - Ge Healthcare - Pall Corporation - Phenomenex, Inc. - Thermo Fisher Scientific Inc. For more information visit http://www.researchandmarkets.com/research/nv...ked_column
PLL: 97.16 (-0.54), A: 42.49 (-0.13), MRK: 57.60 (+0.09)
Merck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
Business Wire - Fri Apr 24, 12:00AM CDT
--Merck Remains on Track to Submit New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) in First Half of 2015
MRK: 57.60 (+0.09)
If You Live in This State, You May Lose the Choice Whether to Vaccinate Your Kids
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 26, 8:11AM CDT
Source: California State Legislature. California could make it a whole heck of a lot tougher for parents and guardians to choose whether to have their children vaccinated. The Golden State is considering legislation barring the use of the "personal...
MRK: 57.60 (+0.09), GSK: 46.59 (+0.28)
I Called It: What's The Take Home Message?
Pharma Doc - at Seeking Alpha - Sun Apr 26, 12:52AM CDT
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
Merck presents data on two HCV Phase 2s at Liver Meeting
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 6:05PM CDT
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09)
Preliminary data show 100% SVR4 for Viekirax + Exviera
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 4:48PM CDT
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), ENTA: 37.14 (+0.56)
Are Biosimilars the Next Big Thing in Biotech?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 25, 6:06AM CDT
Biologics, or drugs developed from biological sources, have taken the pharma world by storm over the past decade or so. Five of the top 10 best-selling drugs in 2014, for example, were biologics indicated for either autoimmune disorders or cancer. ...
PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 5:28PM CDT
Merck reported encouraging data from an ongoing pivotal phase III program evaluating its grazoprevir/elbasvir.
BIIB: 401.71 (-28.57), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:36PM CDT
AbbVie's (ABBV) experimental HCV treatment is under priority review in the U.S. for the treatment of adults suffering from chronic genotype 4 HCV infection.
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AVEO: 1.92 (-0.08), ABBV: 66.07 (+1.82)
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), PRGO: 192.89 (-8.74), PFE: 35.27 (-0.09), CLDN: 13.68 (-0.26), MYL: 76.06 (+2.37), OREX: 7.36 (-0.08), JNJ: 101.08 (+0.62), NVO: 56.65 (+0.44), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), GILD: 103.69 (-1.52), SGEN: 37.14 (-0.36), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), SNY: 51.75 (-0.01), NBY: 0.63 (unch), XLRN: 33.29 (-0.95)
The Parade of Weak Earnings Reports Continues - Earnings Preview
Sheraz Mian - ZACKS - Fri Apr 24, 2:39PM CDT
The Parade of Weak Earnings Reports Continues - Earnings Preview
ACT: 295.41 (-2.95), F: 15.77 (+0.01), ETN: 68.58 (-0.52), PFE: 35.27 (-0.09), IP: 53.67 (+0.79), COP: 67.51 (-0.75), XOM: 86.97 (-0.57), BAC: 15.64 (-0.05), UPS: 98.10 (-0.12), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), CVS: 101.58 (+0.70), CVX: 109.87 (-0.10), AAPL: 130.28 (+0.61), VIAB: 70.74 (+0.04), MA: 90.72 (-0.16)
'Non-Cyclical Consumer Healthcare': How This Sector Will Create Long-Term Wealth
Peter Mantas - Seeking Alpha - Fri Apr 24, 1:39PM CDT
Allow me to provide you with a hypothetical portfolio containing only 5 stocks. This portfolio is somewhat diversified in that each company operates in different markets with different threats, competitors and opportunities, but all 5 companies have...
MCK: 229.20 (+0.09), AKRX: 55.24 (-0.68), PFE: 35.27 (-0.09), EW: 138.33 (-3.59), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), MOH: 63.85 (-0.13), ORCL: 43.08 (-0.31), CNC: 73.67 (+1.13), JNJ: 101.08 (+0.62), ANTM: 154.28 (+0.08), VRSK: 72.68 (+0.20), GILD: 103.69 (-1.52), RMD: 65.70 (-7.68), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), FICO: 93.85 (+0.55), WCN: 46.52 (+0.32), SRCL: 136.94 (-3.56), SNY: 51.75 (-0.01), ACN: 93.40 (-0.44), NVS: 104.28 (-1.22)
Business events scheduled for the coming week
By The Associated Press - AP - Fri Apr 24, 12:28PM CDT
All times are Eastern.
GT: 27.74 (unch), F: 15.77 (+0.01), V: 67.48 (-0.24), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), CVS: 101.58 (+0.70), XOM: 86.97 (-0.57), BRK.B: 142.09 (-0.34), TWTR: 50.82 (-0.59), BRK.A: 214,490.00 (-250.00), AET: 108.82 (-0.08), AAPL: 130.28 (+0.61)
Merck (MRK) Approaches New Upside Target of $58.28
Comtex SmarTrend(R) - Fri Apr 24, 9:36AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $57.46 today and have reached the first resistance level of $57.89. Should the shares continue to rise, the resistance pivots of $58.28 and $59.09 will be of interest.
MRK: 57.60 (+0.09)
Illumina's Earnings Set Positive Tone for Biotech
Cheryl Swanson, The Motley Fool - Motley Fool - Fri Apr 24, 9:02AM CDT
Illumina just lit up a lot of biotech portfolios. Thanks to record-breaking shipments of gene-sequencing instruments, total quarterly revenue surged 28% to $539 million.. Despite facing currency headwinds, the company handily beat the $524.45...
JNJ: 101.08 (+0.62), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), AMGN: 167.91 (-1.26), ILMN: 189.59 (-3.01), SNY: 51.75 (-0.01)
"Merck More Than A Mother " a new initiative in partnership with Nairobi university and university of Indonesia to address the social suffering of infertile women in Indonesia , Kenya and rest of Africa as part of Merck Capacity Advancement Pro
M2 - Fri Apr 24, 8:14AM CDT
Merck in collaboration with University of Indonesia kicked off two important initiatives "More than A Mother" and "Fertility is a Shared Responsibility" to address the social suffering and stigmatization of infertile women as part of Merck Capacity Advancement program (CAP) in fertility management in Indonesia. Same program will be launched in Kenya in partnership with University of Nairobi.
MRK: 57.60 (+0.09)
Merck's HCV combo shows cure rates of 60 - 100% in three genotypes
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 8:05AM CDT
JNJ: 101.08 (+0.62), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)
Merck Announces Results from C-SURFER Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease
CNW Group - Fri Apr 24, 6:00AM CDT
As well as results from its Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Showing High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
MRK: 57.60 (+0.09)
Global Prepacked Column (1-100 mL, 100-1000 mL, -1L) Market 2015-2019 - Forecasts and Analysis of the $700+ Million Market
M2 - Fri Apr 24, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nvfdmm/prepacked_column) has announced the addition of the "Prepacked Column Market by Type (1-100 mL, 100-1000 mL, -1L) - Global Forecast to 2019" report to their offering. The market for pre-packed disposable columns (typically -1 liter size), was valued at $717.1 million in 2014, and is expected to increase at the highest CAGR from 2014 to 2019 The global prepacked chromatography columns market is estimated to grow at a CAGR of 8.2% from 2014 to 2019. Rising demand of purification of antibodies, recombinant proteins, vaccines; and virus titer reduction are some of the factors driving the growth of pre-packed columns market. The cost-effective purification of biological drugs, specifically monoclonal antibodies (mAbs) has been increasing the market potential of pre-packed columns. However, there is a paradigm shift towards disposable pre-packed columns. In this report, the Global Prepacked Chromatography Columns market is broadly classified on the basis of product types and it includes 1-100 ml, 100-1000 ml, and -1L. The market segmented on the basis of regions covers North America, Europe, Asia-Pacific and Rest of the World (RoW). The market in North America accounted the largest share for 33.6% in 2014, followed by the Asia-Pacific market. Currently, in the U.S., mAbs constitute the single largest biologics product category in the clinical development pipeline including the number of monoclonal antibodies (mAbs) in development and clinical trials, biosimilar developments, and facility expansions using single-use strategies. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Global Prepacked Chromatography Columns Market,By Type 6 Prepacked Chromatography Columns Market,By Geography 7 Global Prepacked Chromatography Columns Market: Competitive Landscape 8 Prepacked Chromatography Columns Market, By Company - Agilent Technologies - Atoll Gmbh - Bio-Rad Laboratories, Inc. - Emd Millipore/ Merck Millipore (A Division Of Merck Kgaa) - Ge Healthcare - Pall Corporation - Phenomenex, Inc. - Thermo Fisher Scientific Inc. For more information visit http://www.researchandmarkets.com/research/nv...ked_column
PLL: 97.16 (-0.54), A: 42.49 (-0.13), MRK: 57.60 (+0.09)
Merck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
Business Wire - Fri Apr 24, 12:00AM CDT
--Merck Remains on Track to Submit New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) in First Half of 2015
MRK: 57.60 (+0.09)
